PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 27499034-5 2016 DNA-dependent protein kinase catalytic subunit (DNA-PKcs) and P-glycoprotein (P-gp) were expressed at higher levels in the CD133+ MG-63 cells compared with those levels in the CD133- MG-63 cells, whereas downregulation of DNA-PKcs by small interfering RNA (siRNA) decreased chemoresistance to CDDP and P-gp expression at the mRNA and protein levels in these cells. Cisplatin 293-297 ATP binding cassette subfamily B member 1 Homo sapiens 78-82 27893429-0 2016 MicroRNA-595 sensitizes ovarian cancer cells to cisplatin by targeting ABCB1. Cisplatin 48-57 ATP binding cassette subfamily B member 1 Homo sapiens 71-76 27893429-8 2016 In addition, overexpression of ABCB1 decreased the miR-595-overexpressing HO8910PM and SKOV-3 cell sensitivity to cisplatin. Cisplatin 114-123 ATP binding cassette subfamily B member 1 Homo sapiens 31-36 27629782-8 2016 The results suggest that combined treatment with AKRs (1B10 and 1C3) and ABCB1 inhibitors exerts overcoming effect against the cancer resistance to DTX and cisplatin, and can be used as the adjuvant therapy. Cisplatin 156-165 ATP binding cassette subfamily B member 1 Homo sapiens 73-78 27995666-0 2016 Hypermethylation of ATP-binding cassette B1 (ABCB1) multidrug resistance 1 (MDR1) is associated with cisplatin resistance in the A549 lung adenocarcinoma cell line. Cisplatin 101-110 ATP binding cassette subfamily B member 1 Homo sapiens 20-43 27995666-0 2016 Hypermethylation of ATP-binding cassette B1 (ABCB1) multidrug resistance 1 (MDR1) is associated with cisplatin resistance in the A549 lung adenocarcinoma cell line. Cisplatin 101-110 ATP binding cassette subfamily B member 1 Homo sapiens 45-50 27995666-0 2016 Hypermethylation of ATP-binding cassette B1 (ABCB1) multidrug resistance 1 (MDR1) is associated with cisplatin resistance in the A549 lung adenocarcinoma cell line. Cisplatin 101-110 ATP binding cassette subfamily B member 1 Homo sapiens 52-74 27995666-0 2016 Hypermethylation of ATP-binding cassette B1 (ABCB1) multidrug resistance 1 (MDR1) is associated with cisplatin resistance in the A549 lung adenocarcinoma cell line. Cisplatin 101-110 ATP binding cassette subfamily B member 1 Homo sapiens 76-80 27995666-2 2016 In this study, the major purpose was to assess the expression and methylation levels of ABCB1 in human lung adenocarcinoma and to reveal the relationship between these processes and acquisition of cisplatin (DDP) resistance in the human cancer cell line A549. Cisplatin 197-206 ATP binding cassette subfamily B member 1 Homo sapiens 88-93 27995666-5 2016 Our results showed that the onset of resistance to the cisplatin analogue, DDP, was associated with hypermethylation of the ABCB1 gene. Cisplatin 55-64 ATP binding cassette subfamily B member 1 Homo sapiens 124-129 27995666-8 2016 In conclusion, this in vitro and human tissue study of lung adenocarcinoma cells demonstrated that hypermethylation of the ABCB1 gene correlated with increased gene expression and was associated with the acquisition of resistance to the cisplatin analogue, DDP in human lung adenocarcinoma cells. Cisplatin 237-246 ATP binding cassette subfamily B member 1 Homo sapiens 123-128 27284014-4 2016 We determined that our established PTX-resistant cancer cells display ABCB1/ABCC1-associated cross-resistance to chemically different drugs such as 5-fluorouracil, docetaxel, and cisplatin. Cisplatin 179-188 ATP binding cassette subfamily B member 1 Homo sapiens 70-75 27460719-0 2016 Inhibition of the JNK signaling pathway increases sensitivity of hepatocellular carcinoma cells to cisplatin by down-regulating expression of P-glycoprotein. Cisplatin 99-108 ATP binding cassette subfamily B member 1 Homo sapiens 142-156 27572875-6 2016 Additionally, ketoconazole, a PXR antagonist, suppressed the augmented MDR1 expression and PXR-mediated transactivation by paclitaxel and cisplatin, and enhanced cell growth inhibition and apoptosis in their presence. Cisplatin 138-147 ATP binding cassette subfamily B member 1 Homo sapiens 71-75 27295567-4 2016 The present study describes that the surviving fraction of cisplatin resistant cells co- upregulate MDR1, BMI1 and acetyl transferase activity of TIP60. Cisplatin 59-68 ATP binding cassette subfamily B member 1 Homo sapiens 100-104 27295567-7 2016 Chromatin immunoprecipitation (ChIP) assays further establish that the proximal MDR1 promoter responds to cisplatin in a BMI1 dependent manner. Cisplatin 106-115 ATP binding cassette subfamily B member 1 Homo sapiens 80-84 27295567-9 2016 Collectively, our data establish a hitherto unknown liaison among MDR1, BMI1 and TIP60 and provide mechanistic insights into cisplatin-induced MDR1 expression resulting in acquired cross-resistance against paclitaxel, doxorubicin and likely other drugs. Cisplatin 125-134 ATP binding cassette subfamily B member 1 Homo sapiens 143-147 26647959-8 2016 The further mechanism investigation suggested that prolonged time of cisplatin-treatment contributed to the activation of the NF-kappaB signal, resulting in the upregulation of EMT markers, the maintenance of stem cell marker and the elevated expression of ABCB1. Cisplatin 69-78 ATP binding cassette subfamily B member 1 Homo sapiens 257-262 27013200-0 2016 Human Helicase RECQL4 Drives Cisplatin Resistance in Gastric Cancer by Activating an AKT-YB1-MDR1 Signaling Pathway. Cisplatin 29-38 ATP binding cassette subfamily B member 1 Homo sapiens 93-97 27013200-6 2016 Notably, ectopic expression of RECQL4 in cisplatin-sensitive gastric cancer cells with low endogenous RECQL4 was sufficient to render them resistant to cisplatin, in a manner associated with YB1 elevation and MDR1 activation. Cisplatin 41-50 ATP binding cassette subfamily B member 1 Homo sapiens 209-213 26935266-4 2016 Our data further showed swollen endoplasmic reticulum (ER) in the cisplatin-treated HepG2/IR cells with significantly increased levels of glucose-regulated protein 78 (GRP78), phosphorylated protein kinase R-like ER kinase (p-PERK) and P-glycoprotein (P-gp). Cisplatin 66-75 ATP binding cassette subfamily B member 1 Homo sapiens 236-250 26935266-4 2016 Our data further showed swollen endoplasmic reticulum (ER) in the cisplatin-treated HepG2/IR cells with significantly increased levels of glucose-regulated protein 78 (GRP78), phosphorylated protein kinase R-like ER kinase (p-PERK) and P-glycoprotein (P-gp). Cisplatin 66-75 ATP binding cassette subfamily B member 1 Homo sapiens 252-256 27013200-7 2016 Conversely, RECQL4 silencing in cisplatin-resistant gastric cancer cells with high endogenous RECQL4 suppressed YB1 phosphorylation, reduced MDR1 expression, and resensitized cells to cisplatin. Cisplatin 32-41 ATP binding cassette subfamily B member 1 Homo sapiens 141-145 27014910-10 2016 In addition, we revealed that miR-206 overexpression reduced cisplatin resistance and EMT in DDP-resistant cells, partly due to inactivation of MET/PI3K/AKT/mTOR signaling pathway, and subsequent downregulation of MDR1, ZEB1 and Snail expression. Cisplatin 61-70 ATP binding cassette subfamily B member 1 Homo sapiens 214-218 26717965-0 2016 HIF-1alpha/MDR1 pathway confers chemoresistance to cisplatin in bladder cancer. Cisplatin 51-60 ATP binding cassette subfamily B member 1 Homo sapiens 11-15 26407653-3 2015 The results showed the over-expression of cyclooxygenase-2 and P-glycoprotein in cisplatin-resistant gastric cancer SGC-7901 cells (SGC-7901/DDP), suggesting the possible involvement of cyclooxygenase-2 in the development of P-glycoprotein-mediated drug resistance. Cisplatin 81-90 ATP binding cassette subfamily B member 1 Homo sapiens 63-77 26407653-3 2015 The results showed the over-expression of cyclooxygenase-2 and P-glycoprotein in cisplatin-resistant gastric cancer SGC-7901 cells (SGC-7901/DDP), suggesting the possible involvement of cyclooxygenase-2 in the development of P-glycoprotein-mediated drug resistance. Cisplatin 81-90 ATP binding cassette subfamily B member 1 Homo sapiens 225-239 26626440-0 2015 MicroRNA-186 induces sensitivity of ovarian cancer cells to paclitaxel and cisplatin by targeting ABCB1. Cisplatin 75-84 ATP binding cassette subfamily B member 1 Homo sapiens 98-103 26626440-12 2015 CONCLUSION: Our results are the first to demonstrate that miR-186 may sensitize ovarian cancer cell to paclitaxel and cisplatin by targeting ABCB1 and modulating the expression of GST-pi. Cisplatin 118-127 ATP binding cassette subfamily B member 1 Homo sapiens 141-146 26043084-11 2015 Furthermore, overexpression of miR-130a could increase the MDR1 mRNA and P-gp levels in A2780 and A2780/DDP cells, whereas knockdown of miR-130a could inhibit MDR1 gene expression and upregulate the PTEN protein expression .In a conclusion, the deregulation of miR-374a and miR-130a may be involved in the development and regulation of cisplatin resistance in ovarian cancer cells. Cisplatin 336-345 ATP binding cassette subfamily B member 1 Homo sapiens 159-163 25959925-4 2015 Cisplatin-resistant A549R cells treated with Ru@L-SeNPs-siRNA demonstrated significant downregulation of P-glycoprotein (P-gp) expression, resulting in unprecedented enhanced cytotoxicity through the induction of apoptosis with the involvement of phosphorylation of p53, MAPK and PI3K/Akt signaling pathways. Cisplatin 0-9 ATP binding cassette subfamily B member 1 Homo sapiens 105-119 25959925-4 2015 Cisplatin-resistant A549R cells treated with Ru@L-SeNPs-siRNA demonstrated significant downregulation of P-glycoprotein (P-gp) expression, resulting in unprecedented enhanced cytotoxicity through the induction of apoptosis with the involvement of phosphorylation of p53, MAPK and PI3K/Akt signaling pathways. Cisplatin 0-9 ATP binding cassette subfamily B member 1 Homo sapiens 121-125 26004871-6 2015 We investigated the expression of Gb3, MDR1 and MRP1 in NSCLC and MPM cells with acquired cisplatin resistance, and if GCS activity or MDR1 pump inhibitors would reduce their expression and reverse cisplatin-resistance. Cisplatin 198-207 ATP binding cassette subfamily B member 1 Homo sapiens 135-139 26063766-5 2015 GCS and P-gp expression were significantly associated with cisplatin resistance in several HNC cell lines (P = 0.007). Cisplatin 59-68 ATP binding cassette subfamily B member 1 Homo sapiens 8-12 26063766-8 2015 GCS inhibition increased cisplatin-induced cell death in HNC cells via P-gp downregulation and proapoptotic protein activation, which were abrogated by siPUMA transfection. Cisplatin 25-34 ATP binding cassette subfamily B member 1 Homo sapiens 71-75 26063766-10 2015 GCS and P-gp overexpression is associated with acquired cisplatin resistance, suggesting a role for these molecules as therapeutic targets for HNC. Cisplatin 56-65 ATP binding cassette subfamily B member 1 Homo sapiens 8-12 25308861-5 2015 After Protein Kinase B (PKB/Akt) signal pathway was inhibited by the p-Akt inhibitor (LY294002) and the expression of MRP1 was restrained by siRNA of MRP1, CCK-8 was used to examine the cell proliferation after treatment with cisplatin. Cisplatin 226-235 ATP binding cassette subfamily B member 1 Homo sapiens 118-122 25960213-4 2015 We have used Schrodinger suite 2014, to perform homology modelling of human MDR1 based on Mouse MDR1, followed by Induced Fit Docking with Paclitaxel, Docetaxel, Gemcitabine, Carboplatin and Cisplatin drugs. Cisplatin 191-200 ATP binding cassette subfamily B member 1 Homo sapiens 76-80 25308861-5 2015 After Protein Kinase B (PKB/Akt) signal pathway was inhibited by the p-Akt inhibitor (LY294002) and the expression of MRP1 was restrained by siRNA of MRP1, CCK-8 was used to examine the cell proliferation after treatment with cisplatin. Cisplatin 226-235 ATP binding cassette subfamily B member 1 Homo sapiens 150-154 25308861-7 2015 The increased expression of p-Akt, XIAP, and MRP1 in SKOV3/DDP cells after cisplatin treatment was also repressed by the downregulation of MyD88. Cisplatin 75-84 ATP binding cassette subfamily B member 1 Homo sapiens 45-49 25308861-8 2015 Furthermore, the inhibition of PKB/Akt signal pathway or expression of MRP1 both could decrease the cisplatin resistance of SKOV3/DDP cells and the IC50 decreased to 75 and 53 % of the control group (P < 0.01, P < 0.05), respectively. Cisplatin 100-109 ATP binding cassette subfamily B member 1 Homo sapiens 71-75 23038675-3 2012 Gb(3)Cer was increased in all resistant cells, irrespective of whether the resistance was to paclitaxel or cisplatin, and expression of the MDR1 gene and gangliosides was enhanced in paclitaxel-resistant cells, but gangliosides were absent in cisplatin-resistant cells. Cisplatin 243-252 ATP binding cassette subfamily B member 1 Homo sapiens 140-144 25253429-0 2015 MDR1 and cytochrome P450 gene-expression profiles as markers of chemosensitivity in human chronic myelogenous leukemia cells treated with cisplatin and Ru(III) metallocomplexes. Cisplatin 138-147 ATP binding cassette subfamily B member 1 Homo sapiens 0-4 25253429-4 2015 The present study aimed to investigate the relationship between the expression of MDR1 and CYP450 genes in human chronic myelogenous leukemia cells (K-562) treated with cisplatin (cisPt) and two ruthenium-based coordinated complexes [cisCRu(III) and cisDRu(III)]. Cisplatin 169-178 ATP binding cassette subfamily B member 1 Homo sapiens 82-86 25253429-4 2015 The present study aimed to investigate the relationship between the expression of MDR1 and CYP450 genes in human chronic myelogenous leukemia cells (K-562) treated with cisplatin (cisPt) and two ruthenium-based coordinated complexes [cisCRu(III) and cisDRu(III)]. Cisplatin 180-185 ATP binding cassette subfamily B member 1 Homo sapiens 82-86 25579168-0 2015 Sorafenib reverses resistance of gastric cancer to treatment by cisplatin through down-regulating MDR1 expression. Cisplatin 64-73 ATP binding cassette subfamily B member 1 Homo sapiens 98-102 25579168-8 2015 Sorafenib may reverse resistance of human gastric cancer cell line SGC7901/DDP to cisplatin through down-regulating MDR1 expression. Cisplatin 82-91 ATP binding cassette subfamily B member 1 Homo sapiens 116-120 25560468-7 2015 CONCLUSION: These in vitro results suggest that mRNA expression levels of the RRM1 and ABCB1 genes may be useful indicators of chemosensitivity to gemcitabine and cisplatin, respectively. Cisplatin 163-172 ATP binding cassette subfamily B member 1 Homo sapiens 87-92 25099308-0 2014 Decreased P-glycoprotein is associated with the inhibitory effects of static magnetic fields and cisplatin on K562 cells. Cisplatin 97-106 ATP binding cassette subfamily B member 1 Homo sapiens 10-24 25099308-6 2014 By contrast, in the SMF + DDP group, P-gp expression decreased compared with the DDP group (P < 0.05). Cisplatin 26-29 ATP binding cassette subfamily B member 1 Homo sapiens 37-41 23956061-5 2014 PEITC inhibited cisplatin-resistant human SGC7901/DDP cell growth in a dose-dependent manner, causing increased apoptosis, ROS generation, glutathione depletion, accumulation of Rhodamine-123, decreased expression of P-glycoprotein and cell cycle arrest. Cisplatin 16-25 ATP binding cassette subfamily B member 1 Homo sapiens 217-231 25276252-3 2014 AIM: To study the effect of tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) combined with chemotherapeutic drug cisplatin (DDP) on the expression of multidrug resistance gene 1 (MDR1) in the gastric cancer cell line SGC-7901/VCR. Cisplatin 129-138 ATP binding cassette subfamily B member 1 Homo sapiens 166-193 25276252-3 2014 AIM: To study the effect of tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) combined with chemotherapeutic drug cisplatin (DDP) on the expression of multidrug resistance gene 1 (MDR1) in the gastric cancer cell line SGC-7901/VCR. Cisplatin 129-138 ATP binding cassette subfamily B member 1 Homo sapiens 195-199 24062304-10 2013 Consequently, a lysosomal Pgp-mediated mechanism of MDR was not found for non-ionizable Pgp substrates (e.g. colchicine or paclitaxel) or ionizable non-Pgp substrates (e.g. cisplatin or carboplatin). Cisplatin 173-182 ATP binding cassette subfamily B member 1 Homo sapiens 26-29 23917396-0 2013 Curcumin-loaded nanoparticles induce apoptotic cell death through regulation of the function of MDR1 and reactive oxygen species in cisplatin-resistant CAR human oral cancer cells. Cisplatin 132-141 ATP binding cassette subfamily B member 1 Homo sapiens 96-100 23466650-3 2013 Using the MTT assay, we found that DABB and DHBB could enhance the cytotoxicities of ABCB1 substrates doxorubicin, vincristine, and paclitaxel in ABCB1-overexpressing HepG2/ADM and MCF-7/ADR cells, whereas that of a non-ABCB1 substrate cisplatin was unaffected. Cisplatin 236-245 ATP binding cassette subfamily B member 1 Homo sapiens 85-90 23672493-9 2013 RESULTS: CDDP-resistant gastric cancer cells exhibit ABCB1 and CDKN2A gene up-regulation, as compared with CDDP-sensitive gastric cancer cells. Cisplatin 9-13 ATP binding cassette subfamily B member 1 Homo sapiens 53-58 23135908-5 2013 Treatment of H460 and H661 cell lines with low-dose cisplatin (IC(20)) was sufficient to enrich CD133(+) cells, to induce DNA damage responses, and to upregulate ABCG2 and ABCB1 expression, which therefore increased the cross-resistance to doxorubicin and paclitaxel. Cisplatin 52-61 ATP binding cassette subfamily B member 1 Homo sapiens 172-177 22989452-1 2012 BACKGROUND: The aim of this study is to investigate the effect of Src tyrosine kinase inhibition on the drug-resistance as well as the expression of multidrug resistance 1 (MDR1) and lung resistance-related protein (LRP) of the human cis-platinum-resistant lung cancer cell line A549/DDP. Cisplatin 234-246 ATP binding cassette subfamily B member 1 Homo sapiens 149-171 22543673-3 2012 PATIENTS AND METHODS: This study aimed to evaluate the associations between ABCB1 polymorphisms G2677T/A, C3435T, and their haplotype with progression-free survival (PFS) and overall survival (OS) in 177 SCLC patients treated with cisplatin-etoposide or cyclophosphamide-epirubicin-vincristine chemotherapy. Cisplatin 231-240 ATP binding cassette subfamily B member 1 Homo sapiens 76-81 22989452-1 2012 BACKGROUND: The aim of this study is to investigate the effect of Src tyrosine kinase inhibition on the drug-resistance as well as the expression of multidrug resistance 1 (MDR1) and lung resistance-related protein (LRP) of the human cis-platinum-resistant lung cancer cell line A549/DDP. Cisplatin 234-246 ATP binding cassette subfamily B member 1 Homo sapiens 173-177 22432540-0 2012 Decreased expression of MDR1 in PEG-conjugated hemoglobin solution combined cisplatin treatment in a tumor xenograft model. Cisplatin 76-85 ATP binding cassette subfamily B member 1 Homo sapiens 24-28 23152886-7 2012 The characterization of DRSPs revealed the upregulation of the drug-resistance-related genes ABCG2 and MDR-1 and of CSC-representative markers, suggesting that DRSPs have greater resistance to cisplatin (Cis) and stronger CSC properties compared with the control. Cisplatin 193-202 ATP binding cassette subfamily B member 1 Homo sapiens 103-108 22245869-7 2012 Collectively, these findings suggest that Twist1-mediated modulation of MDR1/P-gp expression plays an important role in sensitization of cervical cancer cells to cisplatin, and also indicate a novel therapeutic strategy to overcome drug resistance through inactivation of Twist1 expression in cervical cancer. Cisplatin 162-171 ATP binding cassette subfamily B member 1 Homo sapiens 72-76 22364296-6 2012 On the other hand, knockdown of p15 expression significantly up-regulated the expression of P-glycoprotein (P-gp) in HepG2/CDDP/2.0 cells, associated with the increased resistance of HepG2 cells to CDDP in vitro. Cisplatin 123-127 ATP binding cassette subfamily B member 1 Homo sapiens 92-106 22364296-6 2012 On the other hand, knockdown of p15 expression significantly up-regulated the expression of P-glycoprotein (P-gp) in HepG2/CDDP/2.0 cells, associated with the increased resistance of HepG2 cells to CDDP in vitro. Cisplatin 123-127 ATP binding cassette subfamily B member 1 Homo sapiens 108-112 22364296-6 2012 On the other hand, knockdown of p15 expression significantly up-regulated the expression of P-glycoprotein (P-gp) in HepG2/CDDP/2.0 cells, associated with the increased resistance of HepG2 cells to CDDP in vitro. Cisplatin 198-202 ATP binding cassette subfamily B member 1 Homo sapiens 92-106 22364296-6 2012 On the other hand, knockdown of p15 expression significantly up-regulated the expression of P-glycoprotein (P-gp) in HepG2/CDDP/2.0 cells, associated with the increased resistance of HepG2 cells to CDDP in vitro. Cisplatin 198-202 ATP binding cassette subfamily B member 1 Homo sapiens 108-112 22432540-1 2012 This study aims to examine the contribution of PEG-conjugated hemoglobin combined with cisplatin to the expression of HIF-1alpha and MDR1 in a tumor xenograft model. Cisplatin 87-96 ATP binding cassette subfamily B member 1 Homo sapiens 133-137 22614869-11 2012 Moreover, downregulation of miR-130a could inhibit MDR1 mRNA and P-gp expression and overcome the cisplatin resistance in SKOV3/CIS cells, which indicated that miR-130a may be associated with MDR1/P-gp-mediated drug resistance and plays the role of an intermediate in drug-resistance pathways of PI3K/Akt/PTEN/mTOR and ABC superfamily drug transporters in SKOV3/CIS cells. Cisplatin 110-119 ATP binding cassette subfamily B member 1 Homo sapiens 63-67 22614869-11 2012 Moreover, downregulation of miR-130a could inhibit MDR1 mRNA and P-gp expression and overcome the cisplatin resistance in SKOV3/CIS cells, which indicated that miR-130a may be associated with MDR1/P-gp-mediated drug resistance and plays the role of an intermediate in drug-resistance pathways of PI3K/Akt/PTEN/mTOR and ABC superfamily drug transporters in SKOV3/CIS cells. Cisplatin 110-119 ATP binding cassette subfamily B member 1 Homo sapiens 228-232 22614869-11 2012 Moreover, downregulation of miR-130a could inhibit MDR1 mRNA and P-gp expression and overcome the cisplatin resistance in SKOV3/CIS cells, which indicated that miR-130a may be associated with MDR1/P-gp-mediated drug resistance and plays the role of an intermediate in drug-resistance pathways of PI3K/Akt/PTEN/mTOR and ABC superfamily drug transporters in SKOV3/CIS cells. Cisplatin 110-119 ATP binding cassette subfamily B member 1 Homo sapiens 233-237 22701315-4 2012 METHODS AND RESULTS: We report that carbonate apatite-mediated delivery of the siRNAs targeting ABCG2 and ABCB1 gene transcripts in human breast cancer cells which constitutively express both of the transporter genes dose-dependently enhanced chemosensitivity to doxorubicin, paclitaxel and cisplatin, the traditionally used chemotherapeutic agents. Cisplatin 291-300 ATP binding cassette subfamily B member 1 Homo sapiens 106-111 21325069-6 2011 The cell lines expressing MDR-1 acquired resistance to chemotherapeutic agents such as cisplatin and doxorubicin, but not bortezomib. Cisplatin 87-96 ATP binding cassette subfamily B member 1 Homo sapiens 26-31 21805041-10 2011 In summary, the endogenous expression of P-gp, MRP, LRP, GST-pi and TopoIIalpha was different in the four human lung cancer cell lines of different histological types, and this variance may be associated with the variation in chemosensitivity to cisplatin, doxorubicin and VP-16. Cisplatin 246-255 ATP binding cassette subfamily B member 1 Homo sapiens 41-45 20856196-8 2011 Using APE1-downregulated cells and cells overexpressing wild-type APE1 or its nonacetylable mutant, we have demonstrated that the loss of APE1"s acetylation impaired MDR1 activation and sensitizes the cells to cisplatin or etoposide. Cisplatin 210-219 ATP binding cassette subfamily B member 1 Homo sapiens 166-170 21332314-5 2011 We examined the ABCB1 gene polymorphism C3435T to predict response and prognosis to neoadjuvant radiochemotherapy (cisplatin, 5-fluorouracil and 36 Gy) in locally advanced esophageal cancer patients. Cisplatin 115-124 ATP binding cassette subfamily B member 1 Homo sapiens 16-21 20627363-0 2011 Single nucleotide polymorphisms in MDR1 gen correlates with outcome in advanced non-small-cell lung cancer patients treated with cisplatin plus vinorelbine. Cisplatin 129-138 ATP binding cassette subfamily B member 1 Homo sapiens 35-39 20627363-2 2011 In this study, we assessed whether the presence of polymorphisms in ERCC1, XPD, RRM1 and MDR1 genes can affect the efficacy and the tolerability of cisplatin and vinorelbine in NSCLC patients. Cisplatin 148-157 ATP binding cassette subfamily B member 1 Homo sapiens 89-93 20689757-2 2010 We hypothesized that assessing the gene expression of the chemotherapy response modifiers multidrug resistance gene 1 (MDR1) and excision repair cross-complementing 1 (ERCC1) may help identify the group of patients benefiting from cisplatin-based adjuvant chemotherapy. Cisplatin 231-240 ATP binding cassette subfamily B member 1 Homo sapiens 119-123 20944142-0 2010 Down-regulation of P-glycoprotein is associated with resistance to cisplatin and VP-16 in human lung cancer cell lines. Cisplatin 67-76 ATP binding cassette subfamily B member 1 Homo sapiens 19-33 20944142-1 2010 AIM: To investigate whether down-regulation of P-glycoprotein (P-gp) is correlated to resistance to cisplatin and VP-16 in four histopathological subtype cell lines of lung cancer (SK-MES-1, SPCA-1, NCI-H-460 and NCI-H-446). Cisplatin 100-109 ATP binding cassette subfamily B member 1 Homo sapiens 47-61 20944142-1 2010 AIM: To investigate whether down-regulation of P-glycoprotein (P-gp) is correlated to resistance to cisplatin and VP-16 in four histopathological subtype cell lines of lung cancer (SK-MES-1, SPCA-1, NCI-H-460 and NCI-H-446). Cisplatin 100-109 ATP binding cassette subfamily B member 1 Homo sapiens 63-67 20944142-6 2010 CONCLUSION: Down-regulation of P-gp is associated with intrinsic resistance to cisplatin in the NCI-H-446 and to VP-16 in SPCA-1, NCI-H-460 and NCI-H-446 cell lines. Cisplatin 79-88 ATP binding cassette subfamily B member 1 Homo sapiens 31-35 20689757-8 2010 CONCLUSIONS: High MDR1 and ERCC1 gene expressions are associated with inferior outcome after cisplatin-based adjuvant chemotherapy for locally advanced bladder cancer. Cisplatin 93-102 ATP binding cassette subfamily B member 1 Homo sapiens 18-22 20458768-10 2010 CONCLUSION: Multiple drug resistance of multiple drugs in the human hepatoma cell line SK-Hep-1/CDDP was closely related to the overexpression of MDR1 and MRP1. Cisplatin 96-100 ATP binding cassette subfamily B member 1 Homo sapiens 146-150 19875192-7 2010 CONCLUSION: Assessment of MRP1 and LRP mRNA expression in TBB specimens may predict histopathologic response and survival in locally advanced NSCLC patients who received neoadjuvant cisplatin-based chemotherapy. Cisplatin 182-191 ATP binding cassette subfamily B member 1 Homo sapiens 26-30 20168208-12 2010 ABCB1 was highly overexpressed in the three most oxaliplatin-resistant sublines, but significantly underexpressed in the two most cisplatin-resistant cell lines. Cisplatin 130-139 ATP binding cassette subfamily B member 1 Homo sapiens 0-5 18812689-0 2009 MDR1 single nucleotide polymorphism G2677T/A and haplotype are correlated with response to docetaxel-cisplatin chemotherapy in patients with non-small-cell lung cancer. Cisplatin 101-110 ATP binding cassette subfamily B member 1 Homo sapiens 0-4 20189873-0 2010 Association of MDR1 and ERCC1 polymorphisms with response and toxicity to cisplatin-based chemotherapy in non-small-cell lung cancer patients. Cisplatin 74-83 ATP binding cassette subfamily B member 1 Homo sapiens 15-19 20628484-4 2010 Of the four ABC transporters (ABCB1, ABCC1, ABCC2 and ABCG2) related to MDR, only ABCC2 was found to be elevated both in CDDP-resistant sublines, with ABCC2 located in nucleus of CNE2-CDDP-5Fu but not in CNE2-CDDP and parental CNE2. Cisplatin 121-125 ATP binding cassette subfamily B member 1 Homo sapiens 30-35 20628484-4 2010 Of the four ABC transporters (ABCB1, ABCC1, ABCC2 and ABCG2) related to MDR, only ABCC2 was found to be elevated both in CDDP-resistant sublines, with ABCC2 located in nucleus of CNE2-CDDP-5Fu but not in CNE2-CDDP and parental CNE2. Cisplatin 184-188 ATP binding cassette subfamily B member 1 Homo sapiens 30-35 19733628-0 2009 Increase in morphine antinociceptive activity by a P-glycoprotein inhibitor in cisplatin-induced neuropathy. Cisplatin 79-88 ATP binding cassette subfamily B member 1 Homo sapiens 51-65 19733628-4 2009 Previous works presented an increase of P-glycoprotein in vincristine- and cisplatin-induced neuropathy which could potentially decrease opioid efficiency. Cisplatin 75-84 ATP binding cassette subfamily B member 1 Homo sapiens 40-54 19900859-9 2009 CONCLUSION: Our data suggested that determination of MRP1, LRP, and ERCC1 mRNA expression using RT-PCR in TBB samples might be helpful in predicting outcome of patients with advanced NSCLC treated with cisplatin-based chemotherapy and in optimizing therapeutic strategy based on the expression of these genes. Cisplatin 202-211 ATP binding cassette subfamily B member 1 Homo sapiens 53-57 18812689-9 2009 CONCLUSION: Our findings suggest that the MDR1 2677G>T/A polymorphism and the 2677G-3435C haplotype are predictors of treatment response to docetaxel-cisplatin chemotherapy in NSCLC patients. Cisplatin 153-162 ATP binding cassette subfamily B member 1 Homo sapiens 42-46 18231753-1 2007 To investigate the relationship between MDR1 and MDR3 gene and drug resistance to cisplatin of ovarian cancer cells. Cisplatin 82-91 ATP binding cassette subfamily B member 1 Homo sapiens 40-44 18809583-6 2008 APE1 downregulation sensitizes MDR1-overexpressing tumor cells to cisplatin or doxorubicin, showing APE1"s critical role in YB-1-mediated gene expression and, thus, drug resistance in tumor cells. Cisplatin 66-75 ATP binding cassette subfamily B member 1 Homo sapiens 31-35 19000447-9 2008 The inhibition rates of paclitaxel (PTX), oxaliplatin (OXA) or cisplatin (DDP) on cancer cells were significantly lower in the group with strong P-gp expression than that with weak P-gp expression (all P<0.05). Cisplatin 63-72 ATP binding cassette subfamily B member 1 Homo sapiens 145-149 19000447-9 2008 The inhibition rates of paclitaxel (PTX), oxaliplatin (OXA) or cisplatin (DDP) on cancer cells were significantly lower in the group with strong P-gp expression than that with weak P-gp expression (all P<0.05). Cisplatin 63-72 ATP binding cassette subfamily B member 1 Homo sapiens 181-185 17611393-2 2007 P-gp and CD147/CD98hc complex are both found highly expressed on cisplatin resistant ovarian cancer cell line SKOV3/DDP but only slightly expressed on its parent cell SKOV3. Cisplatin 65-74 ATP binding cassette subfamily B member 1 Homo sapiens 0-4 17190787-1 2007 By comparing ovarian carcinoma-derived KF28 cells with the corresponding anticancer drug-resistant cells, the taxol- and cisplatin-resistant properties were found to be closely related with MDR1 and BSEP, and MRP2 transporters, respectively. Cisplatin 121-130 ATP binding cassette subfamily B member 1 Homo sapiens 190-194 17374987-3 2007 METHODS: The cisplatin (DDP)-resistant human tongue squamous cell carcinoma cell line Tca8113/DDP, which highly expresses the MDR1 gene, was established by exposure to gradually increasing concentrations of cisplatin. Cisplatin 13-22 ATP binding cassette subfamily B member 1 Homo sapiens 126-130 17374987-3 2007 METHODS: The cisplatin (DDP)-resistant human tongue squamous cell carcinoma cell line Tca8113/DDP, which highly expresses the MDR1 gene, was established by exposure to gradually increasing concentrations of cisplatin. Cisplatin 207-216 ATP binding cassette subfamily B member 1 Homo sapiens 126-130 16995873-2 2006 In accordance with previous reports, taxol and cisplatin resistance was closely correlated with expression of the multidrug resistance 1 and bile acid export pump, and multidrug resistance-associated protein 2 genes, respectively. Cisplatin 47-56 ATP binding cassette subfamily B member 1 Homo sapiens 114-136 15517878-2 2004 The adenosine triphosphate (ATP) binding cassette (ABC) family of transport proteins, such as the 170 kDa P-glycoprotein (multidrug resistance gene-1; MDR-1) and the 190 kDa multidrug resistance-associated proteins (MRPs), are associated with multidrug resistance, including resistance to CDDP. Cisplatin 289-293 ATP binding cassette subfamily B member 1 Homo sapiens 106-120 16478794-0 2006 MDR1 polymorphisms predict the response to etoposide-cisplatin combination chemotherapy in small cell lung cancer. Cisplatin 53-62 ATP binding cassette subfamily B member 1 Homo sapiens 0-4 16478794-7 2006 CONCLUSIONS: Our findings suggest that the MDR1 2677G>T and 3435C>T polymorphisms can be used for predicting treatment response to etoposide-cisplatin chemotherapy in SCLC patients. Cisplatin 147-156 ATP binding cassette subfamily B member 1 Homo sapiens 43-47 15650019-5 2005 In contrast, the anticancer agents, cisplatin and paclitaxel, strongly activated PXR-mediated transcription through the MDR1-responsive element compared with the CYP3A4-responsive element, whereas these drugs also enhanced the MDR1 expression compared with the CYP3A4 expression. Cisplatin 36-45 ATP binding cassette subfamily B member 1 Homo sapiens 120-124 15650019-5 2005 In contrast, the anticancer agents, cisplatin and paclitaxel, strongly activated PXR-mediated transcription through the MDR1-responsive element compared with the CYP3A4-responsive element, whereas these drugs also enhanced the MDR1 expression compared with the CYP3A4 expression. Cisplatin 36-45 ATP binding cassette subfamily B member 1 Homo sapiens 227-231 16026610-6 2005 RESULTS: In 8/16 paired esophageal biopsies, there was an increase in the expression of multi-drug resistance gene 1 (MDR1) following epirubicin + cisplatin + 5-fluorouracil (ECF) chemotherapy and this was accompanied by increased expression of the MDR-1 encoded protein, P-gp. Cisplatin 147-156 ATP binding cassette subfamily B member 1 Homo sapiens 88-116 16026610-6 2005 RESULTS: In 8/16 paired esophageal biopsies, there was an increase in the expression of multi-drug resistance gene 1 (MDR1) following epirubicin + cisplatin + 5-fluorouracil (ECF) chemotherapy and this was accompanied by increased expression of the MDR-1 encoded protein, P-gp. Cisplatin 147-156 ATP binding cassette subfamily B member 1 Homo sapiens 118-122 16026610-6 2005 RESULTS: In 8/16 paired esophageal biopsies, there was an increase in the expression of multi-drug resistance gene 1 (MDR1) following epirubicin + cisplatin + 5-fluorouracil (ECF) chemotherapy and this was accompanied by increased expression of the MDR-1 encoded protein, P-gp. Cisplatin 147-156 ATP binding cassette subfamily B member 1 Homo sapiens 249-254 15643508-8 2005 Interestingly, although DOC, but not CDDP has been reported to be a substrate of P-gp, P-gp expression was significantly inversely correlated with CDDP sensitivity in pulmonary adenocarcinomas (p=0.03). Cisplatin 147-151 ATP binding cassette subfamily B member 1 Homo sapiens 87-91 15643508-10 2005 On the other hand, positive P-gp expression may be an indicator of enhanced in vitro resistance to CDDP in pulmonary adenocarcinomas. Cisplatin 99-103 ATP binding cassette subfamily B member 1 Homo sapiens 28-32 15517878-2 2004 The adenosine triphosphate (ATP) binding cassette (ABC) family of transport proteins, such as the 170 kDa P-glycoprotein (multidrug resistance gene-1; MDR-1) and the 190 kDa multidrug resistance-associated proteins (MRPs), are associated with multidrug resistance, including resistance to CDDP. Cisplatin 289-293 ATP binding cassette subfamily B member 1 Homo sapiens 151-156 14726695-6 2004 It was found that overexpression of ZNRD1 could sensitize SGC7901 cells to P-glycoprotein (P-gp)-related anticancer drugs (vincristine, adriamycin, etoposide) but not to P-gp-nonrelated drugs (5-fluorouracil and cisplatin), which was accompanied with significantly decreased adriamycin accumulation and retention and increased adriamycin releasing in SGC7901 cells. Cisplatin 212-221 ATP binding cassette subfamily B member 1 Homo sapiens 91-95 15262121-12 2004 The mRNA for MDR-1 was uniquely overexpressed in the cisplatin-resistant cell line A2780-CR9 initially treated with low doses of cisplatin and paclitaxel, but was not amplified in A2780 (P < 0.01). Cisplatin 53-62 ATP binding cassette subfamily B member 1 Homo sapiens 13-18 15262121-12 2004 The mRNA for MDR-1 was uniquely overexpressed in the cisplatin-resistant cell line A2780-CR9 initially treated with low doses of cisplatin and paclitaxel, but was not amplified in A2780 (P < 0.01). Cisplatin 129-138 ATP binding cassette subfamily B member 1 Homo sapiens 13-18 15262121-13 2004 CONCLUSIONS: The acquired resistance to cisplatin in A2780 is potentially due to P-glycoprotein-mediated multidrug resistance. Cisplatin 40-49 ATP binding cassette subfamily B member 1 Homo sapiens 81-95 14671431-5 2003 However, cisplatin, 5-FU and cyclophosphamide are not P-gp substrates, yet cisplatin, 5-FU and possibly cyclophosphamide are purported substrates for multidrug resistance proteins (MRPs) 1 and 2 (known to cause chemotherapy resistance). Cisplatin 75-84 ATP binding cassette subfamily B member 1 Homo sapiens 150-194 16107775-4 2004 The chemosensitivity against 5-FU, SN-38, MMC and CDDP was independent of MDR1 C3435T, MRP1 G2168A, and MRP2 C-24T (C3972T), possibly due to no association with the growth rate of and mRNA expression levels of MDR1, MRP1 and MRP2 in the adenocarcinoma, however, MDR1 C3435T tended to be accompanied with a higher expression of MDR1 mRNA. Cisplatin 50-54 ATP binding cassette subfamily B member 1 Homo sapiens 210-214 16107775-4 2004 The chemosensitivity against 5-FU, SN-38, MMC and CDDP was independent of MDR1 C3435T, MRP1 G2168A, and MRP2 C-24T (C3972T), possibly due to no association with the growth rate of and mRNA expression levels of MDR1, MRP1 and MRP2 in the adenocarcinoma, however, MDR1 C3435T tended to be accompanied with a higher expression of MDR1 mRNA. Cisplatin 50-54 ATP binding cassette subfamily B member 1 Homo sapiens 210-214 16107775-4 2004 The chemosensitivity against 5-FU, SN-38, MMC and CDDP was independent of MDR1 C3435T, MRP1 G2168A, and MRP2 C-24T (C3972T), possibly due to no association with the growth rate of and mRNA expression levels of MDR1, MRP1 and MRP2 in the adenocarcinoma, however, MDR1 C3435T tended to be accompanied with a higher expression of MDR1 mRNA. Cisplatin 50-54 ATP binding cassette subfamily B member 1 Homo sapiens 210-214 12370750-1 2002 We examined the effects of suppressing multidrug resistance-associated protein (MRP) and multidrug resistance 1 (MDR1) gene expression in HCT-8DDP human colon cancer cell lines, which showed both cisplatin and multidrug resistance. Cisplatin 196-205 ATP binding cassette subfamily B member 1 Homo sapiens 113-117 12528803-0 2003 Cisplatin, doxorubicin and paclitaxel induce mdr1 gene transcription in ovarian cancer cell lines. Cisplatin 0-9 ATP binding cassette subfamily B member 1 Homo sapiens 45-49 12142085-3 2002 We show that despite being both nuclear the tetrameric Asp281Gly and the monomeric Asp281GlyLeu344Pro proteins have different properties: only Asp281Gly stimulates the transcription of the multidrug resistance-1 gene promoter and induces cisplatin resistance in Saos-2 cells. Cisplatin 238-247 ATP binding cassette subfamily B member 1 Homo sapiens 189-211 12403069-7 2002 The increases in caspase 3 and 9 activities after treatment with CDDP were suppressed in MDR1-overexpression cells. Cisplatin 65-69 ATP binding cassette subfamily B member 1 Homo sapiens 89-93 12365029-10 2002 In the xenotransplants, MDR1 gene expression was enhanced significantly after chemotherapy (P(CDDP) = 0.008; P(CDDP+PSC) = 0.002). Cisplatin 94-98 ATP binding cassette subfamily B member 1 Homo sapiens 24-28 12403069-5 2002 RESULTS: MDR1 was rapidly upregulated when the cells were exposed to apoptotic stimuli by CDDP. Cisplatin 90-94 ATP binding cassette subfamily B member 1 Homo sapiens 9-13 11745426-3 2001 Increased expression of MDR1, MRP5 and SMRP mRNA was observed 48 hr after the initiation of Adriamycin exposure in human lung cancer PC-14 cells and cisplatin-resistant PC-14/CDDP cells, in a dose-dependent manner as measured by TaqMan real-time RT-PCR. Cisplatin 149-158 ATP binding cassette subfamily B member 1 Homo sapiens 24-28 12403069-6 2002 The increase in Bax mRNA to Bcl-2 mRNA ratio after treatment with CDDP was suppressed in MDR1-overexpressing cells. Cisplatin 66-70 ATP binding cassette subfamily B member 1 Homo sapiens 89-93 11745426-3 2001 Increased expression of MDR1, MRP5 and SMRP mRNA was observed 48 hr after the initiation of Adriamycin exposure in human lung cancer PC-14 cells and cisplatin-resistant PC-14/CDDP cells, in a dose-dependent manner as measured by TaqMan real-time RT-PCR. Cisplatin 175-179 ATP binding cassette subfamily B member 1 Homo sapiens 24-28 11500053-5 2001 The cisplatin-resistant HCT-8 cells (HCT-8DDP cells) overexpressed MRP and MDR1 genes, and showed resistance to not only cisplatin (CDDP), but also doxorubicin (DOX) and etoposide (VP-16). Cisplatin 4-13 ATP binding cassette subfamily B member 1 Homo sapiens 75-79 14994074-12 2001 The expression of P-gp and GST-pi in Tca8113/CDDP was much higher than that in Tca8113, which was the proof of the up-regulating translation of MDR-1 mRNA. Cisplatin 45-49 ATP binding cassette subfamily B member 1 Homo sapiens 144-149 10764626-1 2000 The P-glycoprotein (P-gp)-negative epidermoid pharyngeal carcinoma cells KB-3-1 were grown in 0.25 mM benzo[a]pyrene (BaP) for 3 months and increased resistance to doxorubicin, but not to vinblastine, colchicine, or cisplatin, was found. Cisplatin 216-225 ATP binding cassette subfamily B member 1 Homo sapiens 4-18 10433011-2 1999 The signals of the MDR1, MRP, topoisomerase IIalpha, and topoisomerase IIbeta genes in HepG2 were weakened when IFN-alpha was added to CDDP. Cisplatin 135-139 ATP binding cassette subfamily B member 1 Homo sapiens 19-23 10601617-2 2000 The cell line expressing high levels of P-glycoprotein (P-gp), COLO 320 DM, was susceptible to chemosensitization by the experimental agents for the P-gp substrates (paclitaxel, taxotere, daunorubicin, vinblastine and doxorubicin) but not for cisplatin. Cisplatin 243-252 ATP binding cassette subfamily B member 1 Homo sapiens 40-54 10601617-2 2000 The cell line expressing high levels of P-glycoprotein (P-gp), COLO 320 DM, was susceptible to chemosensitization by the experimental agents for the P-gp substrates (paclitaxel, taxotere, daunorubicin, vinblastine and doxorubicin) but not for cisplatin. Cisplatin 243-252 ATP binding cassette subfamily B member 1 Homo sapiens 56-60 10433011-3 1999 In SK-Hep-1, the administration of CDDP alone increased the signals of MDR1 while the addition of IFN-alpha decreased the signals, and the signals of GST-pi were decreased by IFN-alpha plus CDDP. Cisplatin 35-39 ATP binding cassette subfamily B member 1 Homo sapiens 71-75 11817335-9 1999 Induction of P-GP expression was observed in some specimens after treatment with MMC and with CDDP. Cisplatin 94-98 ATP binding cassette subfamily B member 1 Homo sapiens 13-17 1905705-11 1991 Drug resistance genes related to the treated drug were also expressed in this in vivo model; MDR1 in SW480/DXR, GST-pi in SW480/CDDP and in SC1NU/CDDP and TS in SW480/5-FU. Cisplatin 128-132 ATP binding cassette subfamily B member 1 Homo sapiens 93-97 8611717-3 1996 In cytotoxicity studies in vitro, combinations of the immunotoxin with cisplatin produced supra-additive killing effects on both Namalwa and Namalwa/mdr-1 cells, whereas anti-B4-bR combined with 4-hydroperoxy-cyclophosphamide caused additive killing of both cell lines. Cisplatin 71-80 ATP binding cassette subfamily B member 1 Homo sapiens 149-154 8704279-0 1995 P-glycoprotein expression in ovarian cancer cell line following treatment with cisplatin. Cisplatin 79-88 ATP binding cassette subfamily B member 1 Homo sapiens 0-14 8704279-7 1995 Our results suggest that cisplatin can cause Pgp expression, and that both cisplatin-resistance and Pgp-mediated MDR phenotypes can coexist in some tumor types. Cisplatin 25-34 ATP binding cassette subfamily B member 1 Homo sapiens 45-48 7848886-1 1994 BACKGROUND: To determine the expression of P-glycoprotein in pre- and post-chemotherapy tumor tissue samples from patients with transitional cell carcinomas treated with M-VAC (methotrexate, vinblastine, adriamycin and cisplatin). Cisplatin 219-228 ATP binding cassette subfamily B member 1 Homo sapiens 43-57 8518026-3 1993 A substantial (14- to 39-fold) enhancement of vinblastine toxicity to highly multidrug-resistant (MCF-7Adr) cells expressing P-glycoprotein was also observed in the presence of tamoxifen, toremifene and their metabolites, while m-amsacrine, cisplatin and melphalan toxicity was unaffected. Cisplatin 241-250 ATP binding cassette subfamily B member 1 Homo sapiens 125-139 1334113-6 1992 Seven out of eight of the confirmed MDR1 samples were resistant to either cis-platinum or alkylating agents or to both. Cisplatin 74-86 ATP binding cassette subfamily B member 1 Homo sapiens 36-40 9815817-7 1997 Suppression of P-glycoprotein expression was also observed with subtoxic doses of the DNA cross-linking agents cisplatin, BMS181174, and chromium(VI). Cisplatin 111-120 ATP binding cassette subfamily B member 1 Homo sapiens 15-29 8599869-10 1996 These observations imply that cisplatin-resistant cells may be more sensitive to mitotic spindle poisons and vinca alkaloids, irrespective of the mechanism of platinum resistance, and that the cytotoxicity of vinca alkaloids could be further modulated by verapamil, irrespective of the presence or absence of P-glycoprotein. Cisplatin 30-39 ATP binding cassette subfamily B member 1 Homo sapiens 309-323 8543635-1 1995 The multidrug resistance gene product P-glycoprotein (P-GP) was assessed immunohistochemically (by antibody JSB-1) in biopsy specimens from 27 oesophageal squamous carcinomas and 10 adenocarcinomas before treatment with mitomycin, ifosfamide and cisplatin (MIC). Cisplatin 246-255 ATP binding cassette subfamily B member 1 Homo sapiens 38-52 8543635-1 1995 The multidrug resistance gene product P-glycoprotein (P-GP) was assessed immunohistochemically (by antibody JSB-1) in biopsy specimens from 27 oesophageal squamous carcinomas and 10 adenocarcinomas before treatment with mitomycin, ifosfamide and cisplatin (MIC). Cisplatin 246-255 ATP binding cassette subfamily B member 1 Homo sapiens 54-58 8835287-3 1995 Dihydrocytochalasin B and cytochalasin E consistently sensitized P-glycoprotein-overexpressing human breast carcinoma cells (MCF-7/ADR) to daunomycin, vinblastine, and actinomycin D without affecting the cytotoxicity of cisplatin. Cisplatin 220-229 ATP binding cassette subfamily B member 1 Homo sapiens 65-79 7914378-4 1994 The succinate dehydrogenase (SD) activity for each drug of P-gp positive and negative tumors was as follows: 81.8 +/- 15.2% vs. 66.3 +/- 16.1% for Adriamycin (ADM), 75.5 +/- 14.2% vs. 59.1 +/- 17.6% for aclacinomycin A (ACR), 71.7 +/- 15.0% vs. 61.1 +/- 14.0% for mitomycin C (MMC), and 57.5 +/- 18.4% vs. 47.0 +/- 16.7% for cisplatin (CDDP). Cisplatin 325-334 ATP binding cassette subfamily B member 1 Homo sapiens 59-63 7914378-4 1994 The succinate dehydrogenase (SD) activity for each drug of P-gp positive and negative tumors was as follows: 81.8 +/- 15.2% vs. 66.3 +/- 16.1% for Adriamycin (ADM), 75.5 +/- 14.2% vs. 59.1 +/- 17.6% for aclacinomycin A (ACR), 71.7 +/- 15.0% vs. 61.1 +/- 14.0% for mitomycin C (MMC), and 57.5 +/- 18.4% vs. 47.0 +/- 16.7% for cisplatin (CDDP). Cisplatin 336-340 ATP binding cassette subfamily B member 1 Homo sapiens 59-63 7946563-0 1994 Expression of P-glycoprotein and in vitro or in vivo resistance to doxorubicin and cisplatin in breast and ovarian cancers. Cisplatin 83-92 ATP binding cassette subfamily B member 1 Homo sapiens 14-28 7903668-16 1993 MDR1-related resistance appeared to play a role in the failure of SCLC-6 chemotherapy; frequent recurrences after treatment with cisplatin and Cpa, two drugs that are not recognized by the P-glycoprotein, indicated that other modes of resistance were simultaneously active. Cisplatin 129-138 ATP binding cassette subfamily B member 1 Homo sapiens 0-4 1905705-11 1991 Drug resistance genes related to the treated drug were also expressed in this in vivo model; MDR1 in SW480/DXR, GST-pi in SW480/CDDP and in SC1NU/CDDP and TS in SW480/5-FU. Cisplatin 146-150 ATP binding cassette subfamily B member 1 Homo sapiens 93-97 2369137-3 1990 Recently, expression of MDR gene and synthesis of p-glycoprotein by the MDR gene was reported as a mode of multi-drug resistance, but the mechanism of the resistance to cisplatinum (CDDP) remains unclear. Cisplatin 169-180 ATP binding cassette subfamily B member 1 Homo sapiens 50-64 2369137-3 1990 Recently, expression of MDR gene and synthesis of p-glycoprotein by the MDR gene was reported as a mode of multi-drug resistance, but the mechanism of the resistance to cisplatinum (CDDP) remains unclear. Cisplatin 182-186 ATP binding cassette subfamily B member 1 Homo sapiens 50-64 33813077-10 2021 Furthermore, multidrug resistance protein 1 (MDR-1) expression levels were dramatically decreased in OS cells with cDDP resistance when CHD1L was suppressed. Cisplatin 115-119 ATP binding cassette subfamily B member 1 Homo sapiens 45-50 33813077-10 2021 Furthermore, multidrug resistance protein 1 (MDR-1) expression levels were dramatically decreased in OS cells with cDDP resistance when CHD1L was suppressed. Cisplatin 115-119 ATP binding cassette subfamily B member 1 Homo sapiens 13-43 34290520-1 2021 Objective: The present study aims to investigate the correlation between the gene polymorphisms of the multidrug resistance protein 1 (ABCB1), the intron region of transcriptional factor (GTF2E1) and catechol-O-methyltransferase (COMT), dopamine receptor (DRD2), and the control of chemotherapy-induced nausea and vomiting (CINV) by olanzapine or aprepitant in a Chinese population under a fractionated cisplatin dosing pattern. Cisplatin 403-412 ATP binding cassette subfamily B member 1 Homo sapiens 103-133 34931793-3 2022 Herein, multidrug resistance protein 1 (MDR1) siRNA is used as the skeleton to assemble chemotherapeutic cisplatin (CDDP) and divalent copper ion (Cu2+) for constructing a carrier-free Cu-siMDR-CDDP system. Cisplatin 105-114 ATP binding cassette subfamily B member 1 Homo sapiens 8-38 34931793-3 2022 Herein, multidrug resistance protein 1 (MDR1) siRNA is used as the skeleton to assemble chemotherapeutic cisplatin (CDDP) and divalent copper ion (Cu2+) for constructing a carrier-free Cu-siMDR-CDDP system. Cisplatin 105-114 ATP binding cassette subfamily B member 1 Homo sapiens 40-44 34931793-3 2022 Herein, multidrug resistance protein 1 (MDR1) siRNA is used as the skeleton to assemble chemotherapeutic cisplatin (CDDP) and divalent copper ion (Cu2+) for constructing a carrier-free Cu-siMDR-CDDP system. Cisplatin 116-120 ATP binding cassette subfamily B member 1 Homo sapiens 8-38 34931793-3 2022 Herein, multidrug resistance protein 1 (MDR1) siRNA is used as the skeleton to assemble chemotherapeutic cisplatin (CDDP) and divalent copper ion (Cu2+) for constructing a carrier-free Cu-siMDR-CDDP system. Cisplatin 116-120 ATP binding cassette subfamily B member 1 Homo sapiens 40-44 34931793-7 2022 Besides, delivery of MDR1 siRNA is facilitated by HO -triggered lysosome destruction, thus inhibiting P-glycoprotein (P-gp) expression and CDDP efflux. Cisplatin 139-143 ATP binding cassette subfamily B member 1 Homo sapiens 21-25 34499772-11 2021 Taken together, PDCD4-pAKT-pYB1 forms the integrated molecular network to regulate MDR1 transcription during the process of stemness-associated cisplatin resistance. Cisplatin 144-153 ATP binding cassette subfamily B member 1 Homo sapiens 83-87 34306203-12 2021 Thus, the present study indicated that circRNA_103615 may serve as a critical oncogene and potential novel biomarker in NSCLC, as well as a potential cisplatin resistance promoter, by regulating ABCB1 expression. Cisplatin 150-159 ATP binding cassette subfamily B member 1 Homo sapiens 195-200 34113397-5 2021 In addition, dacomitinib increased Cadherin 1 (CDH1) levels and decreased P-glycoprotein (P-GP) levels in cisplatin-resistant OC cells. Cisplatin 106-115 ATP binding cassette subfamily B member 1 Homo sapiens 90-94 34400945-11 2021 Quantitative RT-PCR showed significant downregulation of CSC markers (Oct4, Nanog, Sox2, Aldh1, Abcb1, CD44, and CD133) and Snail, epithelial-mesenchymal transition marker, after treatment with menadione and cisplatin/gemcitabine. Cisplatin 208-217 ATP binding cassette subfamily B member 1 Homo sapiens 96-101 35285843-5 2022 In addition, these novel Pt complexes reversed cisplatin-induced resistance via inhibiting the expression of P-glycoprotein and decreasing the level of glutathione in A549cisR cells. Cisplatin 47-56 ATP binding cassette subfamily B member 1 Homo sapiens 109-123 35592418-7 2022 This effect was more pronounced in cisplatin-resistant LUAD cells with high MDR1 expression. Cisplatin 35-44 ATP binding cassette subfamily B member 1 Homo sapiens 76-80 35609308-2 2022 According to our former research, asiatic acid (AA) re-sensitized A549/DDP cells to cisplatin (DDP) through decreasing multidrug resistance protein 1 (MDR1) expression level. Cisplatin 84-93 ATP binding cassette subfamily B member 1 Homo sapiens 119-149 35609308-2 2022 According to our former research, asiatic acid (AA) re-sensitized A549/DDP cells to cisplatin (DDP) through decreasing multidrug resistance protein 1 (MDR1) expression level. Cisplatin 84-93 ATP binding cassette subfamily B member 1 Homo sapiens 151-155 35233464-6 2022 Cisplatin resistance was assessed by detecting P-glycoprotein (P-gp) level, half maximal inhibitory concentration (IC50) of cisplatin and cell apoptosis. Cisplatin 0-9 ATP binding cassette subfamily B member 1 Homo sapiens 47-61 35233464-6 2022 Cisplatin resistance was assessed by detecting P-glycoprotein (P-gp) level, half maximal inhibitory concentration (IC50) of cisplatin and cell apoptosis. Cisplatin 0-9 ATP binding cassette subfamily B member 1 Homo sapiens 63-67 34053427-11 2022 (5) Significantly, the combination of Celastrol and DDP reduced the expression of P-gp, MRP1, and BCRP in the SGC7901/DPP cells. Cisplatin 52-55 ATP binding cassette subfamily B member 1 Homo sapiens 82-86 2914273-9 1989 Differential sensitivities among the five cell lines to 5-fluorouracil, cisplatinum, and bleomycin appear to be mediated through other mechanism beside the mdr-1 gene. Cisplatin 72-83 ATP binding cassette subfamily B member 1 Homo sapiens 156-161 33325136-6 2021 Exosomes derived from CDDP-resistant cells were shown to reduce the sensitivity of MG63 and U2OS cells to CDDP, inhibit apoptosis, and increase the expression of multidrug resistance-associated protein 1 and P-glycoprotein. Cisplatin 22-26 ATP binding cassette subfamily B member 1 Homo sapiens 208-222 33976698-0 2021 Nucleolin Promotes Cisplatin Resistance in Cervical Cancer by the YB1-MDR1 Pathway. Cisplatin 19-28 ATP binding cassette subfamily B member 1 Homo sapiens 70-74 33720323-13 2021 In conclusion, exosomal LINC00355 derived from CAFs promotes BC cell resistance to cisplatin by regulating the miR-34b-5p/ABCB1 axis. Cisplatin 83-92 ATP binding cassette subfamily B member 1 Homo sapiens 122-127 33247530-0 2021 Circular RNA circ_0004507 contributes to laryngeal cancer progression and cisplatin resistance by sponging miR-873 to upregulate multidrug resistance 1 and multidrug resistance protein 1. Cisplatin 74-83 ATP binding cassette subfamily B member 1 Homo sapiens 129-151 33247530-0 2021 Circular RNA circ_0004507 contributes to laryngeal cancer progression and cisplatin resistance by sponging miR-873 to upregulate multidrug resistance 1 and multidrug resistance protein 1. Cisplatin 74-83 ATP binding cassette subfamily B member 1 Homo sapiens 156-186 33456714-0 2021 Correction: Cepharanthine hydrochloride reverses the mdr1 (P-glycoprotein)-mediated esophageal squamous cell carcinoma cell cisplatin resistance through JNK and p53 signals. Cisplatin 124-133 ATP binding cassette subfamily B member 1 Homo sapiens 53-57 33627632-8 2021 The interaction between RCP and P-gp was verified endogenously and loss of RCP or mutant p53 rendered cells more sensitive to cisplatin and etoposide. Cisplatin 126-135 ATP binding cassette subfamily B member 1 Homo sapiens 32-36 32918990-18 2021 Furthermore, we found that ABC drug efflux transporters MDR1, MRP2, and BCRP in CDDP treated HepG2 cells were decreased when pretreated with KLT. Cisplatin 80-84 ATP binding cassette subfamily B member 1 Homo sapiens 56-60 32627280-10 2020 In conclusion, deoxyshikonin suppressed cisplatin resistance in cisplatin-resistant NSCLC cells by repressing Akt signaling-mediated ABCB1 expression. Cisplatin 64-73 ATP binding cassette subfamily B member 1 Homo sapiens 133-138 33084601-11 2020 Inhibition of miR-202-5p and overexpression of ABCB1 eliminated the effects of NORAD silence on cisplatin resistance of A549/DDP cells. Cisplatin 96-105 ATP binding cassette subfamily B member 1 Homo sapiens 47-52 32376584-9 2020 In cultured HNE1 cells, inhibition of the expression of miR129 significantly promoted autophagy and up-regulated P-gp expression (P < 0.01); Chloroquine obviously inhibited cisplatin-induced autophagy and up-regulated the expression of miR129 in HNE1 cells (P < 0.01). Cisplatin 173-182 ATP binding cassette subfamily B member 1 Homo sapiens 113-117 32758011-0 2022 Circ_0109291 Promotes the Cisplatin Resistance of Oral Squamous Cell Carcinoma by Sponging miR-188-3p to Increase ABCB1 Expression. Cisplatin 26-35 ATP binding cassette subfamily B member 1 Homo sapiens 114-119 32748110-0 2020 ABCB1 and ABCC2 genetic polymorphism as risk factors for neutropenia in esophageal cancer patients treated with docetaxel, cisplatin, and 5-fluorouracil chemotherapy. Cisplatin 123-132 ATP binding cassette subfamily B member 1 Homo sapiens 0-5 32124932-0 2020 Hesperetin reverses P-glycoprotein-mediated cisplatin resistance in DDP-resistant human lung cancer cells via modulation of the nuclear factor-kappaB signaling pathway. Cisplatin 44-53 ATP binding cassette subfamily B member 1 Homo sapiens 20-34 32700607-8 2021 Real-time PCR showed that phytol was more effective that RA and cisplatin in down-regulating the CSC markers OCT4, NANOG, SOX2, ALDH1, ABCB1, CD44 and CD133. Cisplatin 64-73 ATP binding cassette subfamily B member 1 Homo sapiens 135-140 32428872-8 2020 These results indicate that AR upregulates ABCB1 expression through the PI3K/Akt/NF-kappaB signaling pathway and thus contributes to cisplatin resistance in chondrosarcoma. Cisplatin 133-142 ATP binding cassette subfamily B member 1 Homo sapiens 43-48 32131547-4 2020 High expression levels of MDR1 were the cause of cisplatin resistance in T24R2 cells, and cordycepin significantly reduced MDR1 expression through inhibition of MDR1 promoter activity. Cisplatin 49-58 ATP binding cassette subfamily B member 1 Homo sapiens 26-30 32355733-8 2020 Cisplatin-resistant variants were confirmed by higher half maximal inhibitory concentration (IC50) values and increased P-glycoprotein (ABCB1, P-gp) expression compared to A2780 cells. Cisplatin 0-9 ATP binding cassette subfamily B member 1 Homo sapiens 136-141 31963452-8 2020 Our findings indicate that TiO2 PEG NPs enhance cisplatin cytotoxicity by down regulating P-gp and that TiO2 PEG NPs are promising candidates for inhibiting P-gp and reversing drug resistance acquired by cancer cells. Cisplatin 48-57 ATP binding cassette subfamily B member 1 Homo sapiens 90-94 31539112-0 2019 Long non-coding RNA ROR regulated ABCB1 to induce cisplatin resistance in osteosarcoma by sponging miR-153-3p. Cisplatin 50-59 ATP binding cassette subfamily B member 1 Homo sapiens 34-39 32767949-0 2020 A Ferrocene Derivative Reduces Cisplatin Resistance in Breast Cancer Cells Through Suppression of MDR-1 Expression and Modulation of JAK2/STAT3 Signaling Pathway. Cisplatin 31-40 ATP binding cassette subfamily B member 1 Homo sapiens 98-103 32767949-7 2020 RESULTS: Overexpression of MDR1 as well as a markedly increase in the level of phosphorylated STAT3 was observed in cisplatin-resistant MCF-7 (MCF-7R) cells. Cisplatin 116-125 ATP binding cassette subfamily B member 1 Homo sapiens 27-31 32767949-8 2020 FMSP successfully reduced the MCF-7R cell viability and reversed both MDR1 expression and STAT3 phosphorylation status through which sensitivity of MCF-7R cells to cisplatin treatment was regained. Cisplatin 164-173 ATP binding cassette subfamily B member 1 Homo sapiens 70-74 31350703-1 2019 We previously reported that anti-paclitaxel-resistant ovarian carcinoma cells characteristically expressed the MDR1 (multidrug resistance 1) gene with enhanced synthesis of glycolipids, i.e., LacCer, Gb3Cer, Leb and GM3, and that anti-cisplatin-resistant cells lost GM3. Cisplatin 235-244 ATP binding cassette subfamily B member 1 Homo sapiens 117-139 31539112-5 2019 PATIENTS AND METHODS: The levels of ROR, miR-153-3p, and ABCB1 in cisplatin-resistant OS tissues and cells were detected by qRT-PCR and/or Western blot assay. Cisplatin 66-75 ATP binding cassette subfamily B member 1 Homo sapiens 57-62 31539112-12 2019 CONCLUSIONS: We found that ROR or ABCB1 knockdown can increase the cisplatin sensitivity of MG63/DDP and U2OS/DDP cells. Cisplatin 67-76 ATP binding cassette subfamily B member 1 Homo sapiens 34-39 31539112-13 2019 ROR contributed to cisplatin resistance in OS via miR-153-3p/ABCB1 axis, unraveling a new regulatory network of chemoresistance in cisplatin-resistant OS cells and may provide a therapeutic target for OS patients. Cisplatin 19-28 ATP binding cassette subfamily B member 1 Homo sapiens 61-66 31539112-13 2019 ROR contributed to cisplatin resistance in OS via miR-153-3p/ABCB1 axis, unraveling a new regulatory network of chemoresistance in cisplatin-resistant OS cells and may provide a therapeutic target for OS patients. Cisplatin 131-140 ATP binding cassette subfamily B member 1 Homo sapiens 61-66 31169018-10 2019 LW6-treated A549 cells showed an increase in ROS level that blocked the hypoxia induced resistance to cisplatin and in addition, decreased expression of MDR1 and MRP1 in cisplatin-treated cells. Cisplatin 170-179 ATP binding cassette subfamily B member 1 Homo sapiens 153-157 31350703-1 2019 We previously reported that anti-paclitaxel-resistant ovarian carcinoma cells characteristically expressed the MDR1 (multidrug resistance 1) gene with enhanced synthesis of glycolipids, i.e., LacCer, Gb3Cer, Leb and GM3, and that anti-cisplatin-resistant cells lost GM3. Cisplatin 235-244 ATP binding cassette subfamily B member 1 Homo sapiens 111-115 31312250-1 2019 Background: To investigate the role of P16 (INK4a)-extracellular signal related kinase 1/2 (ERK1/2) signaling pathway in cisplatin (DDP) resistance induced by multidrug resistance protein 1 (MDR1), also known as P-glycoprotein (P-gp), in cervical adenocarcinoma. Cisplatin 121-130 ATP binding cassette subfamily B member 1 Homo sapiens 159-189 31312250-1 2019 Background: To investigate the role of P16 (INK4a)-extracellular signal related kinase 1/2 (ERK1/2) signaling pathway in cisplatin (DDP) resistance induced by multidrug resistance protein 1 (MDR1), also known as P-glycoprotein (P-gp), in cervical adenocarcinoma. Cisplatin 121-130 ATP binding cassette subfamily B member 1 Homo sapiens 191-195 31169018-11 2019 This study revealed that hypoxia-improved cisplatin chemoresistance of NSCLC cells by regulated MDR1 and MRP1 expression via HIF1alpha/ROS pathway is reversed by LW6, suggesting that LW6 may act as effective sensitizer in chemotherapy for NSCLC. Cisplatin 42-51 ATP binding cassette subfamily B member 1 Homo sapiens 96-100 29760419-0 2018 PLGA nanoparticles co-delivering MDR1 and BCL2 siRNA for overcoming resistance of paclitaxel and cisplatin in recurrent or advanced ovarian cancer. Cisplatin 97-106 ATP binding cassette subfamily B member 1 Homo sapiens 33-37 31173289-2 2019 PATIENTS AND METHODS: We detected the expressions of SNHG5, apoptosis-specific genes (Bax and Bcl-2) and drug resistance-specific genes (MDR1 and MRP1) in cisplatin-sensitive and cisplatin-resistant GC patients. Cisplatin 155-164 ATP binding cassette subfamily B member 1 Homo sapiens 137-141 29772519-2 2018 The mechanisms underlying resistance to doxorubicin, cisplatin, and 5-fluorouracil involve p53 and P-glycoprotein (P-gp). Cisplatin 53-62 ATP binding cassette subfamily B member 1 Homo sapiens 99-113 29772519-2 2018 The mechanisms underlying resistance to doxorubicin, cisplatin, and 5-fluorouracil involve p53 and P-glycoprotein (P-gp). Cisplatin 53-62 ATP binding cassette subfamily B member 1 Homo sapiens 115-119 30952710-0 2019 P-Glycoprotein Overexpression Is Associated With Cisplatin Resistance in Human Osteosarcoma. Cisplatin 49-58 ATP binding cassette subfamily B member 1 Homo sapiens 0-14 30952710-8 2019 RESULTS: P-gp expression levels were associated with cisplatin efficacy in OS patients. Cisplatin 53-62 ATP binding cassette subfamily B member 1 Homo sapiens 9-13 30952710-9 2019 OS cells with higher P-gp expression were more resistant to cisplatin. Cisplatin 60-69 ATP binding cassette subfamily B member 1 Homo sapiens 21-25 30952710-10 2019 Knockdown or inhibition of P-gp sensitized OS cells to cisplatin. Cisplatin 55-64 ATP binding cassette subfamily B member 1 Homo sapiens 27-31 30952710-11 2019 CONCLUSION: Down-regulating the expression of P-gp in OS maybe a promising strategy to overcome cisplatin resistance. Cisplatin 96-105 ATP binding cassette subfamily B member 1 Homo sapiens 46-50 30718500-0 2019 CHD1L contributes to cisplatin resistance by upregulating the ABCB1-NF-kappaB axis in human non-small-cell lung cancer. Cisplatin 21-30 ATP binding cassette subfamily B member 1 Homo sapiens 62-67 30718500-9 2019 Knocking down ABCB1 coupled with ectopic expression of CHD1L enhanced the effect of cisplatin on NSCLC cells apoptosis. Cisplatin 84-93 ATP binding cassette subfamily B member 1 Homo sapiens 14-19 30697056-14 2019 Moreover, scutellarin inhibited the expressions of ATP-binding cassette subfamily B member 1 and ATP-binding cassette sub-family G member 2 in cisplatin-resistant glioma cells. Cisplatin 143-152 ATP binding cassette subfamily B member 1 Homo sapiens 51-92 30444043-0 2019 miR-381 overcomes cisplatin resistance in breast cancer by targeting MDR1. Cisplatin 18-27 ATP binding cassette subfamily B member 1 Homo sapiens 69-73 30066890-8 2018 Knockdown of TWIST increased the sensitivity of R-HepG2 cells to 5-fluroracil, cisplatin and doxorubicin through a reduction in MDR1 expression and drug efflux ability. Cisplatin 79-88 ATP binding cassette subfamily B member 1 Homo sapiens 128-132 29760419-6 2018 Our siRNA-loaded PLGA nanoparticles for co-delivering MDR1 and BCL2 siRNA provide an efficient combination therapy strategy to overcome the chemoresistance of paclitaxel and cisplatin on the paclitaxel-resistant SKOV3-TR and cisplatin-resistant A2780-CP20 ovarian cancer respectively. Cisplatin 174-183 ATP binding cassette subfamily B member 1 Homo sapiens 54-58 29760419-6 2018 Our siRNA-loaded PLGA nanoparticles for co-delivering MDR1 and BCL2 siRNA provide an efficient combination therapy strategy to overcome the chemoresistance of paclitaxel and cisplatin on the paclitaxel-resistant SKOV3-TR and cisplatin-resistant A2780-CP20 ovarian cancer respectively. Cisplatin 225-234 ATP binding cassette subfamily B member 1 Homo sapiens 54-58 29171106-0 2018 Autophagy regulates cisplatin-induced stemness and chemoresistance via the upregulation of CD44, ABCB1 and ADAM17 in oral squamous cell carcinoma. Cisplatin 20-29 ATP binding cassette subfamily B member 1 Homo sapiens 97-102 29505924-0 2018 LncRNA-MALAT1 contributes to the cisplatin-resistance of lung cancer by upregulating MRP1 and MDR1 via STAT3 activation. Cisplatin 33-42 ATP binding cassette subfamily B member 1 Homo sapiens 94-98 29798292-5 2018 Western blot assay show the protein expression of Snail and MDR1 were down-regulated in transfected Hep-2/CDDP cells (allP<0.05), while epithelial marker E-cadherin was up-regulated in protein level (P<0.05).Conclusion:Small interference of transcription factor Snail could increase the expression of E-cadherin while decrease the expression of MDR1, and it was confirmed that interference Snail contribute to enhanced cisplatin sensitivity on human laryngeal resistant cancer cells. Cisplatin 425-434 ATP binding cassette subfamily B member 1 Homo sapiens 60-64 29559849-0 2018 Overexpressed circPVT1, a potential new circular RNA biomarker, contributes to doxorubicin and cisplatin resistance of osteosarcoma cells by regulating ABCB1. Cisplatin 95-104 ATP binding cassette subfamily B member 1 Homo sapiens 152-157 29559849-6 2018 In addition, functional assays revealed that circPVT1 knockdown by siRNA could weaken the resistance to doxorubicin and cisplatin of OS cells through decreasing the expression of classical drug resistance-related gene ABCB1. Cisplatin 120-129 ATP binding cassette subfamily B member 1 Homo sapiens 218-223 29171106-7 2018 Further, cisplatin (CDDP)-resistant FaDu cells displayed stem-like features and higher CD44, ABCB1 and ADAM17 expression. Cisplatin 9-18 ATP binding cassette subfamily B member 1 Homo sapiens 93-98 29171106-7 2018 Further, cisplatin (CDDP)-resistant FaDu cells displayed stem-like features and higher CD44, ABCB1 and ADAM17 expression. Cisplatin 20-24 ATP binding cassette subfamily B member 1 Homo sapiens 93-98 29299132-7 2017 Colchicine was used as the substrate for P-glycoprotein (Pgp) and multidrug resistance protein (MRP) 1, cisplatin was used as the substrate for Mrp2 and organic cation transporters 2 (Oct2), and verapamil and MK571 were used as inhibitors of Pgp and MRP1, respectively. Cisplatin 104-113 ATP binding cassette subfamily B member 1 Homo sapiens 41-55 29107111-0 2018 Entinostat reverses cisplatin resistance in esophageal squamous cell carcinoma via down-regulation of multidrug resistance gene 1. Cisplatin 20-29 ATP binding cassette subfamily B member 1 Homo sapiens 102-129 29250186-0 2017 Knockdown of long non-coding RNA HOTAIR sensitizes hepatocellular carcinoma cell to cisplatin by suppressing the STAT3/ABCB1 signaling pathway. Cisplatin 84-93 ATP binding cassette subfamily B member 1 Homo sapiens 119-124 29107111-4 2018 MDR1 expression was associated with worsen survival of ESCC patients with cisplatin-based chemotherapy. Cisplatin 74-83 ATP binding cassette subfamily B member 1 Homo sapiens 0-4 29107111-7 2018 Furthermore, Obatoclax, an inhibitor of Mcl-1, obviously decreased the expression of MDR1, suggesting that entinostat might surmount cisplatin resistance in ESCC via a Src-Mcl-1-MDR1 pathway. Cisplatin 133-142 ATP binding cassette subfamily B member 1 Homo sapiens 85-89 29876362-6 2018 Results: MiR-221 together with proteins MDR1 and ABCG2 was upregulated in Cisplatin-resistant A549 lung cancer cells. Cisplatin 74-83 ATP binding cassette subfamily B member 1 Homo sapiens 40-44 29768255-0 2018 Asiatic Acid (AA) Sensitizes Multidrug-Resistant Human Lung Adenocarcinoma A549/DDP Cells to Cisplatin (DDP) via Downregulation of P-Glycoprotein (MDR1) and Its Targets. Cisplatin 93-102 ATP binding cassette subfamily B member 1 Homo sapiens 131-145 29768255-4 2018 The present study assessed the reversing effect of AA on MDR and possible molecular mechanisms of AA action in MDR1-overexpressing cisplatin (DDP)-resistant lung cancer cells, A549/DDP. Cisplatin 131-140 ATP binding cassette subfamily B member 1 Homo sapiens 111-115 29299132-7 2017 Colchicine was used as the substrate for P-glycoprotein (Pgp) and multidrug resistance protein (MRP) 1, cisplatin was used as the substrate for Mrp2 and organic cation transporters 2 (Oct2), and verapamil and MK571 were used as inhibitors of Pgp and MRP1, respectively. Cisplatin 104-113 ATP binding cassette subfamily B member 1 Homo sapiens 57-60 29299132-7 2017 Colchicine was used as the substrate for P-glycoprotein (Pgp) and multidrug resistance protein (MRP) 1, cisplatin was used as the substrate for Mrp2 and organic cation transporters 2 (Oct2), and verapamil and MK571 were used as inhibitors of Pgp and MRP1, respectively. Cisplatin 104-113 ATP binding cassette subfamily B member 1 Homo sapiens 242-245 29156767-8 2017 In conclusion, TQ significantly augments cisplatin-induced anti-tumor effects on gastric cancer both in vitro and in vivo, through inhibiting PI3K/AKT signaling pathway, activating the mitochondrial pathway, and down-regulating P-glycoprotein by up-regulating PTEN gene. Cisplatin 41-50 ATP binding cassette subfamily B member 1 Homo sapiens 228-242 28721581-5 2017 RNA interference of HOTAIR reduced the proliferation of cisplatin-resistant Ishikawa cells and enhanced the autophagy activity of cisplatin-resistant Ishikawa cells with or without cisplatin treatment, in addition, beclin-1, multidrug resistance (MDR), and P-glycoprotein (P-gp) were mediated by lncRNA HOTAIR. Cisplatin 130-139 ATP binding cassette subfamily B member 1 Homo sapiens 257-271 28721581-5 2017 RNA interference of HOTAIR reduced the proliferation of cisplatin-resistant Ishikawa cells and enhanced the autophagy activity of cisplatin-resistant Ishikawa cells with or without cisplatin treatment, in addition, beclin-1, multidrug resistance (MDR), and P-glycoprotein (P-gp) were mediated by lncRNA HOTAIR. Cisplatin 130-139 ATP binding cassette subfamily B member 1 Homo sapiens 273-277 28721581-5 2017 RNA interference of HOTAIR reduced the proliferation of cisplatin-resistant Ishikawa cells and enhanced the autophagy activity of cisplatin-resistant Ishikawa cells with or without cisplatin treatment, in addition, beclin-1, multidrug resistance (MDR), and P-glycoprotein (P-gp) were mediated by lncRNA HOTAIR. Cisplatin 130-139 ATP binding cassette subfamily B member 1 Homo sapiens 257-271 28721581-5 2017 RNA interference of HOTAIR reduced the proliferation of cisplatin-resistant Ishikawa cells and enhanced the autophagy activity of cisplatin-resistant Ishikawa cells with or without cisplatin treatment, in addition, beclin-1, multidrug resistance (MDR), and P-glycoprotein (P-gp) were mediated by lncRNA HOTAIR. Cisplatin 130-139 ATP binding cassette subfamily B member 1 Homo sapiens 273-277 28721581-6 2017 CONCLUSIONS: It is clear that lncRNAs, specifically HOTAIR, can regulate the cisplatin-resistance ability of human endometrial cancer cells through the regulation of autophagy by influencing Beclin-1, MDR, and P-gp expression. Cisplatin 77-86 ATP binding cassette subfamily B member 1 Homo sapiens 210-214 28422725-0 2017 MiR-199a-3p enhances cisplatin sensitivity of cholangiocarcinoma cells by inhibiting mTOR signaling pathway and expression of MDR1. Cisplatin 21-30 ATP binding cassette subfamily B member 1 Homo sapiens 126-130 28382490-7 2017 Also, we discovered that YB-1 silencing sensitized SH-SY5Y cells to cisplatin and promoted the apoptosis induced by cisplatin due to down-regulation of multidrug resistance (MDR) 1 protein via NF-kappaB signaling pathway. Cisplatin 116-125 ATP binding cassette subfamily B member 1 Homo sapiens 152-180 27484766-0 2017 Efficacy of Aidi Injection () on overexpression of P-glycoprotein induced by vinorelbine and cisplatin regimen in patients with non-small cell lung cancer. Cisplatin 93-102 ATP binding cassette subfamily B member 1 Homo sapiens 51-65 27484766-1 2017 OBJECTIVE: To investigate the efficacy of Aidi Injection () on overexpression of P-glycoprotein (P-gp) induced by vinorelbine and cisplatin (NP) regimen in patients with non-small cell lung cancer (NSCLC), and study the difference between intravenous administration and targeting intratumor administration of Aidi Injection with thoracoscope. Cisplatin 130-139 ATP binding cassette subfamily B member 1 Homo sapiens 81-95 27484766-1 2017 OBJECTIVE: To investigate the efficacy of Aidi Injection () on overexpression of P-glycoprotein (P-gp) induced by vinorelbine and cisplatin (NP) regimen in patients with non-small cell lung cancer (NSCLC), and study the difference between intravenous administration and targeting intratumor administration of Aidi Injection with thoracoscope. Cisplatin 130-139 ATP binding cassette subfamily B member 1 Homo sapiens 97-101 28422725-7 2017 Moreover, we also found that miR-199a-3p overexpression could reduce cisplatin induced MDR1 expression by decreasing the synthesis and increasing the degradation of MDR1, thus enhancing the effectiveness of cisplatin in cholangiocarcinoma. Cisplatin 69-78 ATP binding cassette subfamily B member 1 Homo sapiens 87-91 28422725-7 2017 Moreover, we also found that miR-199a-3p overexpression could reduce cisplatin induced MDR1 expression by decreasing the synthesis and increasing the degradation of MDR1, thus enhancing the effectiveness of cisplatin in cholangiocarcinoma. Cisplatin 69-78 ATP binding cassette subfamily B member 1 Homo sapiens 165-169 28422725-7 2017 Moreover, we also found that miR-199a-3p overexpression could reduce cisplatin induced MDR1 expression by decreasing the synthesis and increasing the degradation of MDR1, thus enhancing the effectiveness of cisplatin in cholangiocarcinoma. Cisplatin 207-216 ATP binding cassette subfamily B member 1 Homo sapiens 87-91 28422725-7 2017 Moreover, we also found that miR-199a-3p overexpression could reduce cisplatin induced MDR1 expression by decreasing the synthesis and increasing the degradation of MDR1, thus enhancing the effectiveness of cisplatin in cholangiocarcinoma. Cisplatin 207-216 ATP binding cassette subfamily B member 1 Homo sapiens 165-169 28422725-8 2017 In conclusion, miR-199a-3p could increase cisplatin sensitivity of cholangiocarcinoma cell lines by inhibiting the activity of the mTOR signaling pathway and decreasing the expression of MDR1. Cisplatin 42-51 ATP binding cassette subfamily B member 1 Homo sapiens 187-191 27200496-0 2017 Epigallocatechin gallate sensitizes cisplatin-resistant oral cancer CAR cell apoptosis and autophagy through stimulating AKT/STAT3 pathway and suppressing multidrug resistance 1 signaling. Cisplatin 36-45 ATP binding cassette subfamily B member 1 Homo sapiens 155-177 28443990-12 2017 Moreover, induced expression of LPAATbeta compromised the effects of miR-340-5p on CDDP-induced cell death and accumulation of MRP1 and MDR1. Cisplatin 83-87 ATP binding cassette subfamily B member 1 Homo sapiens 136-140 28340578-12 2017 In contrast, cisplatin, the frequently used adjuvant chemotherapeutic agent, activated beta-catenin dependent signaling that lead to up-regulation of both ABCB1 and ABCG2 transporter expression and activity. Cisplatin 13-22 ATP binding cassette subfamily B member 1 Homo sapiens 155-160 28340578-14 2017 Cisplatin via induction of canonical Wnt signaling up-regulates ABCB1 and ABCG2 drug transporters that are not transporters for cisplatin itself but are transporters for drugs that are frequently used in combination therapy with cisplatin modulating drug response. Cisplatin 0-9 ATP binding cassette subfamily B member 1 Homo sapiens 64-69 28340578-14 2017 Cisplatin via induction of canonical Wnt signaling up-regulates ABCB1 and ABCG2 drug transporters that are not transporters for cisplatin itself but are transporters for drugs that are frequently used in combination therapy with cisplatin modulating drug response. Cisplatin 128-137 ATP binding cassette subfamily B member 1 Homo sapiens 64-69 28340578-14 2017 Cisplatin via induction of canonical Wnt signaling up-regulates ABCB1 and ABCG2 drug transporters that are not transporters for cisplatin itself but are transporters for drugs that are frequently used in combination therapy with cisplatin modulating drug response. Cisplatin 229-238 ATP binding cassette subfamily B member 1 Homo sapiens 64-69 28340578-0 2017 ABCB1 and ABCG2 drug transporters are differentially expressed in non-small cell lung cancers (NSCLC) and expression is modified by cisplatin treatment via altered Wnt signaling. Cisplatin 132-141 ATP binding cassette subfamily B member 1 Homo sapiens 0-5 28012924-8 2017 Most importantly, we further confirmed that P-gp is the functional target of miR-129 by regulating cisplatin-resistance in GC cells. Cisplatin 99-108 ATP binding cassette subfamily B member 1 Homo sapiens 44-48 28012924-9 2017 These results suggested that miR-129 reversed cisplatin-resistance through inhibiting the P-gp expression in GC cells. Cisplatin 46-55 ATP binding cassette subfamily B member 1 Homo sapiens 90-94 28053596-8 2017 RESULTS: MDR1, MRP1, BCRP and Trkb, E-cadherin, beta-catenin were significantly downregulated in cells treated with the combination of celecoxib and cisplatin, and decreased beta-catenin level was found in cells with wortmannin, a specific PI3K inhibitor. Cisplatin 149-158 ATP binding cassette subfamily B member 1 Homo sapiens 9-13 29979530-7 2017 The sensitivity of cisplatin administration after transfecting GGI/MDR1 siRNA polyplexs was performed with MTT and Annexin V-FITC/PI methods. Cisplatin 19-28 ATP binding cassette subfamily B member 1 Homo sapiens 67-71 27435393-8 2017 Upon CDDP treatment, CEBPD activated ABCB1 and ABCC2. Cisplatin 5-9 ATP binding cassette subfamily B member 1 Homo sapiens 37-42 28012924-0 2017 MiR-129 regulates cisplatin-resistance in human gastric cancer cells by targeting P-gp. Cisplatin 18-27 ATP binding cassette subfamily B member 1 Homo sapiens 82-86